2024
Biologics for Psoriasis
Wride A, Chen G, Spaulding S, Tkachenko E, Cohen J. Biologics for Psoriasis. Dermatologic Clinics 2024, 42: 339-355. PMID: 38796266, DOI: 10.1016/j.det.2024.02.001.Peer-Reviewed Original ResearchConceptsIL-23IL-17ALong-term risk-benefit profileTNF-aLong-term adverse eventsIL-23 inhibitorsTumor necrosis factor-alphaP19 subunit of IL-23Risk-benefit profileSubunit of IL-23TNF-a inhibitorsTreatment of psoriasisNecrosis factor-alphaHigher Psoriasis AreaRates of short-termIL-12/23Psoriasis AreaIL-17FAdverse eventsIL-12IL-17Factor-alphaP19 subunitInjectable biologicsP40 subunit
2022
Provider-level prescription patterns among dermatologists utilizing injectable biologics in psoriasis treatment
Ugwu N, Cheraghlou S, Feng H, Cohen JM. Provider-level prescription patterns among dermatologists utilizing injectable biologics in psoriasis treatment. Journal Of Dermatological Treatment 2022, 33: 2876-2877. PMID: 35509155, DOI: 10.1080/09546634.2022.2071820.Peer-Reviewed Original Research
2020
Early Adoption of Dupilumab in the Medicare Population in 2017.
Cheraghlou S, Cohen JM. Early Adoption of Dupilumab in the Medicare Population in 2017. The Yale Journal Of Biology And Medicine 2020, 93: 675-677. PMID: 33380928, PMCID: PMC7757055.Peer-Reviewed Original ResearchConceptsAtopic dermatitisRural-Urban Continuum CodesMedicare populationHealth Statistics Urban-Rural Classification SchemeInjectable biologicsSevere atopic dermatitisRetrospective cohort studyCohort studyPatient outcomesDupilumabFirst drugMedicare Provider UtilizationFDA approvalUtilization trendsFirst FDAFuture interventionsProvider UtilizationPotential targetBiologicsDisease treatmentPatientsTreatmentFirst yearMore rural regionsContinuum Codes